Clinical Trials
10
Active:9
Completed:1
Trial Phases
2 Phases
Phase 1:8
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Phase 1
8 (80.0%)Phase 2
2 (20.0%)A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)
Phase 2
Active, not recruiting
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Interventions
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Calliditas Therapeutics Suisse SA
- Target Recruit Count
- 55
- Registration Number
- NCT05323656
- Locations
- 🇺🇸
Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
🇺🇸Siteman Cancer Center - West County, Creve Coeur, Missouri, United States
🇺🇸Siteman Cancer Center - North County, Florissant, Missouri, United States
A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness
Phase 2
Completed
- Conditions
- Primary Biliary CholangitisLiver Stiffness
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Calliditas Therapeutics Suisse SA
- Target Recruit Count
- 76
- Registration Number
- NCT05014672
- Locations
- 🇺🇸
UA Thomas D. Boyer Liver Institute, Tucson, Arizona, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸California Liver Research Institute, Pasadena, California, United States
News
No news found